Differential Effects of Lovastatin on Cisplatin Responses in Normal Human Mesothelial Cells versus Cancer Cells: Implication for Therapy

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Shi, Yandong ^a   Felley Bosco, Emanuela ^a   Marti, Thomas M ^a   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GERANYLTRANSFERASE; MEVINOLIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MESOTHELIUM CELL; OXIDATIVE STRESS;

CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; DNA DAMAGE; EPITHELIUM; HUMANS; LOVASTATIN; PROTEIN PRENYLATION; TUMOR CELLS, CULTURED;

EID: 84866460606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045354     Document Type: Article

References (49)

1. Kelland L, (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.
2. Hartwell LH, Kastan MB, (1994) Cell cycle control and cancer. Science 266: 1821-1828.
3. Blagosklonny MV, Pardee AB, (2001) Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 61: 4301-4305.
4. Baserga R, (1994) Oncogenes and the strategy of growth factors. Cell 79: 927-930.
5. Evan G, Littlewood T, (1998) A matter of life and cell death. Science 281: 1317-1322.
6. Blagosklonny MV, Darzynkiewicz Z, (2002) Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle 1: 375-382.
7. McTaggart SJ, (2006) Isoprenylated proteins. Cell Mol Life Sci 63: 255-267.
8. Fritz G, Henninger C, Huelsenbeck J, (2011) Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. Br Med Bull 97: 17-26.
9. Berndt N, Hamilton AD, Sebti SM, (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11: 775-791.
10. Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, et al. (2002) A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 22: 5157-5172.
11. Schmitter D, Lauber B, Fagg B, Stahel RA, (1992) Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51: 296-301.
12. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM, (2011) Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 13: 961-970.
13. Brooks SC, Locke ER, Soule HD, (1973) Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248: 6251-6253.
14. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G, (1976) A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17: 62-70.
15. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, et al. (2000) Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20: 1436-1447.
16. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z, (1991) Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A 88: 3628-3632.
17. Cole SP, (1986) Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 17: 259-263.
18. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, et al. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491.
19. Olive PL, Banath JP, (2009) Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 76: 79-90.
20. Bakkenist CJ, Kastan MB, (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506.
21. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
22. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, et al. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
23. Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, et al. (2010) A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 333: 23-33.
24. Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D, et al. (2010) Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 70: 971-981.
25. Asakura K, Izumi Y, Yamamoto M, Yamauchi Y, Kawai K, et al. (2011) The cytostatic effects of lovastatin on ACC-MESO-1 cells. J Surg Res 170: e197-209.
26. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, et al. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19: 5720-5728.
27. Applegate LA, Luscher P, Tyrrell RM, (1991) Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 51: 974-978.
28. McKnight JA, (2003) Principles of chemotherapy. Clin Tech Small Anim Pract 18: 67-72.
29. Damrot J, Nubel T, Epe B, Roos WP, Kaina B, et al. (2006) Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 149: 988-997.
30. Nubel T, Damrot J, Roos WP, Kaina B, Fritz G, (2006) Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res 12: 933-939.
31. Ostrau C, Hulsenbeck J, Herzog M, Schad A, Torzewski M, et al. (2009) Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother Oncol 92: 492-499.
32. Huelsenbeck J, Henninger C, Schad A, Lackner KJ, Kaina B, et al. (2011) Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2: e190.
33. Bardeleben RV, Dunkern T, Kaina B, Fritz G, (2002) The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med 10: 473-479.
34. Lovric MM, Hawkins CJ, (2010) TRAIL treatment provokes mutations in surviving cells. Oncogene 29: 5048-5060.
35. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
36. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, et al. (2012) Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell 148: 244-258.
37. Rao S, Lowe M, Herliczek TW, Keyomarsi K, (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402.
38. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, et al. (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117: 838-847.
39. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, et al. (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5: 2223-2229.
40. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, et al. (2001) Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7: 158-167.
41. Cafforio P, Dammacco F, Gernone A, Silvestris F, (2005) Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891.
42. Ahn KS, Sethi G, Aggarwal BB, (2008) Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 75: 907-913.
43. Chan DY, Chen GG, Poon WS, Liu PC, (2008) Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol 86: 273-283.
44. Klawitter J, Shokati T, Moll V, Christians U, (2010) Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 12: R16.
45. Gibot L, Follet J, Metges JP, Auvray P, Simon B, et al. (2009) Human caspase 7 is positively controlled by SREBP-1 and SREBP-2. Biochem J 420: 473-483.
46. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M, (1998) Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411.
47. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, et al. (2000) Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6: 2044-2052.
48. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM, (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71: 1763-1771.
49. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, et al. (2008) The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 100: 134-139.